Elevance Health Management
Management criteria checks 3/4
Elevance Health's CEO is Gail Boudreaux, appointed in Nov 2017, has a tenure of 6.5 years. total yearly compensation is $21.89M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth $75.89M. The average tenure of the management team and the board of directors is 6.1 years and 10.8 years respectively.
Key information
Gail Boudreaux
Chief executive officer
US$21.9m
Total compensation
| CEO salary percentage | 7.3% |
| CEO tenure | 6.5yrs |
| CEO ownership | 0.06% |
| Management average tenure | 6.1yrs |
| Board average tenure | 10.8yrs |
Recent management updates
Recent updates
Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63
Apr 25
Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23Is Elevance Health (NYSE:ELV) Using Too Much Debt?
Apr 16Elevance Health: Not Doing Enough In 2024 To Justify Premium Price
Apr 11Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors
Apr 01Elevance: A Healthy Dose Of Dividend Growth
Mar 21Elevance Heath: Financial Growth And Technical Strength Indicate A Buy
Mar 07Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63
Feb 19Elevance Health: Time To Buy This Incredible Dividend Growth Stock
Jan 26Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement
Jan 19Is Elevance Health (NYSE:ELV) A Risky Investment?
Jan 02Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story
Dec 18A Look At Elevance's Margin Dynamics
Nov 23Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?
Nov 16Elevance Health: A High Conviction Defensive Blue Chip Buy
Oct 19These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely
Oct 04Elevance: Pave The Way For The Next UnitedHealth
Sep 21Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Sep 18Here's The Price I Would Buy Elevance Health Stock
Sep 13If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity
Aug 18Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
Aug 04Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental
Jul 24Elevance Health: Beaten Down Share Price Offers Solid Potential
Jul 10Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly
Jul 05Elevance Health: A Critical Update (Rating Downgrade)
Jun 05Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
Jun 04Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
May 05We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt
Apr 04Elevance Health's (NYSE:ELV) Dividend Will Be Increased To $1.48
Feb 17Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Feb 13Elevance Health: Attractive On Its Expansion Catalysts
Feb 09Elevance Health (NYSE:ELV) Has Announced That It Will Be Increasing Its Dividend To $1.48
Jan 28Elevance Health acquiring Blue Cross and Blue Shield of Louisiana
Jan 23Elevance Health Offers Great Value
Jan 17At US$483, Is Elevance Health Inc. (NYSE:ELV) Worth Looking At Closely?
Jan 17Elevance Health: Strong And Steady EPS Growth Ahead, High Relative Strength Name
Jan 02Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Nov 28Does Elevance Health (NYSE:ELV) Deserve A Spot On Your Watchlist?
Nov 16Elevance Health to acquire speciality pharmacy from CarepathRx
Nov 09Elevance Health (NYSE:ELV) Is Doing The Right Things To Multiply Its Share Price
Nov 02Elevance Health declares $1.28 dividend
Oct 19Are Investors Undervaluing Elevance Health Inc. (NYSE:ELV) By 37%?
Oct 12Elevance affiliates to offer affordable Medicare Advantage plans
Oct 10Molina, Elevance, Centene win Medicare contracts in California
Aug 26Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Aug 25Elevance Health: Continues To Grow, A Strong Buy
Aug 18What Does Elevance Health Inc.'s (NYSE:ELV) Share Price Indicate?
Aug 13Elevance Health (NYSE:ELV) Shareholders Will Want The ROCE Trajectory To Continue
Aug 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$22m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$17m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$5b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$15m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$4b |
| Dec 31 2018 | US$14m | US$1m | US$4b |
| Sep 30 2018 | n/a | n/a | US$5b |
| Jun 30 2018 | n/a | n/a | US$4b |
| Mar 31 2018 | n/a | n/a | US$4b |
| Dec 31 2017 | US$3m | US$162k | US$4b |
Compensation vs Market: Gail's total compensation ($USD21.89M) is above average for companies of similar size in the US market ($USD13.53M).
Compensation vs Earnings: Gail's compensation has been consistent with company performance over the past year.
CEO
Gail Boudreaux (62 yo)
6.5yrs
Tenure
US$21,889,039
Compensation
Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.5yrs | US$21.89m | 0.062% $ 75.9m | |
| Executive VP & CFO | less than a year | US$12.36m | no data | |
| EVP, Chief Legal & Administrative Officer | 3.5yrs | US$8.11m | 0.0044% $ 5.4m | |
| Executive VP and President of Carelon & CarelonRx | 9.9yrs | US$6.98m | 0.0063% $ 7.7m | |
| Executive VP & President of Government Health Benefits | 5.9yrs | US$6.48m | 0.0097% $ 11.9m | |
| SVP, Treasurer & Chief Investment Officer | 6.1yrs | no data | no data | |
| Senior VP | 8.5yrs | no data | 0.00057% $ 698.1k | |
| Chief Information Officer | no data | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior Vice President of Public Affairs | 10.5yrs | no data | no data | |
| Chief Strategy Officer & Interim Chief Marketing Officer | less than a year | no data | no data | |
| Executive VP and President of Commercial & Specialty Health Benefits | no data | no data | 0.0050% $ 6.1m |
6.1yrs
Average Tenure
57yo
Average Age
Experienced Management: ELV's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.5yrs | US$21.89m | 0.062% $ 75.9m | |
| Independent Director | 19.5yrs | US$386.76k | 0.0027% $ 3.3m | |
| Independent Chair of the Board | 10.6yrs | US$597.83k | 0% $ 0 | |
| Independent Director | 10.8yrs | US$362.53k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$371.42k | 0% $ 0 | |
| Independent Director | 10yrs | US$371.42k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$347.28k | 0.0013% $ 1.6m | |
| Independent Director | 12.8yrs | US$360.34k | 0.0029% $ 3.6m | |
| Member of Advisory Board | 10.8yrs | no data | no data | |
| Member of Advisory Board | 10.8yrs | no data | no data | |
| Member of Advisory Board | 10.8yrs | no data | no data | |
| Member of Advisory Board | 10.8yrs | no data | no data |
10.8yrs
Average Tenure
67yo
Average Age
Experienced Board: ELV's board of directors are seasoned and experienced ( 10.8 years average tenure).